Replies to post #165681 on Biotech Values

[DewDiligence]

NVO is investing big money in oral-insulin drugs:

http://in.reuters.com/article/2013/10/07/us-novonordisk-diabetes-pills-idINBRE9960D720131007

Novo Nordisk…aims to develop both an insulin and a so-called GLP-1 agonist in tablet form. The company has around 500 employees working on the development of the tablets… It will spend around 1 billion crowns [~$180M] on the projects this year, with investment increasing towards possible product launches early next decade.

[DewDiligence]

CHMP approves GSK’s weekly GLP-1, Eperzan (a/k/a albiglutide):

http://finance.yahoo.com/news/eu-regulator-backs-bayer-gsk-124116415.html

The PDUFA date for the US NDA is 4/15/14 due to a 30-month delay (http://www.gsk.com/media/press-releases/2013/regulatory-update--albiglutide-us-pdufa-date-extended-by-three-m.html ).

The GLP-1 market is pretty crowded already.